Liraglutide
Daily GLP-1 receptor agonist
A shorter-acting GLP-1 analog studied before the weekly agonists, still used as a comparator in metabolic research.
How it works
Fatty-acid acylation extends half-life to roughly 13 hours, giving daily GLP-1 receptor activation with slowed gastric emptying and reduced appetite drive.
What research has shown
Trial literature reports about 8% mean weight reduction at 56 weeks at the higher study dose.
Reported ranges in the literature
Low end
0.6 mg daily (initiation week)
Optimal
1.8 mg daily
High end
3.0 mg daily, the top dose in weight studies
Frequency reported in the literature: Once daily
Protocol duration and pairing
Typical study duration
56 week weight-management protocols, 26 to 52 weeks in glycemic studies.
Best paired with
Daily dosing schedule means it is rarely combined with weekly incretin analogs in study designs.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.